------------------------------------------------------------------------------------------------------------------------

Plain sentence:
---------------
    Genentech Inc. said the West German distributor of its heart drug TPA reached a joint marketing agreement with a
    subsidiary of Hoechst AG, which makes the rival anti-clotting agent streptokinase.

Treebanked sentence:
--------------------
    Genentech Inc. said 0 the West German distributor of its heart drug TPA reached a joint marketing agreement with a
    subsidiary of Hoechst AG , which *T*-1 makes the rival anti-clotting agent streptokinase .

Tree:
-----
    (TOP (S (NP-SBJ (NNP Genentech)
                    (NNP Inc.))
            (VP (VBD said)
                (SBAR (-NONE- 0)
                      (S (NP-SBJ (NP (DT the)
                                     (ADJP (JJ West)
                                           (JJ German))
                                     (NN distributor))
                                 (PP (IN of)
                                     (NP (NP (PRP$ its)
                                             (NN heart)
                                             (NN drug))
                                         (NP (NNP TPA)))))
                         (VP (VBD reached)
                             (NP (DT a)
                                 (JJ joint)
                                 (NN marketing)
                                 (NN agreement))
                             (PP-CLR (IN with)
                                     (NP (NP (DT a)
                                             (NN subsidiary))
                                         (PP (IN of)
                                             (NP (NP (NNP Hoechst)
                                                     (NNP AG))
                                                 (, ,)
                                                 (SBAR (WHNP-1 (WDT which))
                                                       (S (NP-SBJ (-NONE- *T*-1))
                                                          (VP (VBZ makes)
                                                              (NP (NP (DT the)
                                                                      (JJ rival)
                                                                      (JJ anti-clotting)
                                                                      (NN agent))
                                                                  (NP (NNP streptokinase))))))))))))))
            (. .)))

Leaves:
-------
    0   Genentech
           name:  ORG                0-1    Genentech Inc.
    1   Inc.
    2   said
           prop:  say.01
            v          * -> 2:0,  said
            ARG0       * -> 0:1,  Genentech Inc.
            ARG1       * -> 3:1,  0 the West German distributor of its heart drug TPA reached a joint marketing
                                  agreement with a subsidiary of Hoechst AG , which *T*-1 makes the rival anti-clotting
                                  agent streptokinase
    3   0
    4   the
    5   West
    6   German
    7   distributor
    8   of
    9   its
    10  heart
    11  drug
    12  TPA
    13  reached
           prop:  reach.01
            v          * -> 13:0, reached
            ARG0       * -> 4:2,  the West German distributor of its heart drug TPA
            ARG1       * -> 14:1, a joint marketing agreement
                         -> 18:1, with a subsidiary of Hoechst AG , which *T*-1 makes the rival anti-clotting agent
                                  streptokinase
    14  a
    15  joint
    16  marketing
    17  agreement
    18  with
    19  a
    20  subsidiary
    21  of
    22  Hoechst
           name:  ORG                22-23  Hoechst AG
    23  AG
    24  ,
    25  which
    26  *T*-1
    27  makes
           prop:  make.01
            v          * -> 27:0, makes
            ARG0       * -> 26:0, *T*-1 -> 25:1, which
            ARG1       * -> 28:2, the rival anti-clotting agent streptokinase
            LINK-SLC   * -> 22:1, Hoechst AG
                       * -> 26:0, *T*-1 -> 25:1, which
    28  the
    29  rival
    30  anti-clotting
    31  agent
    32  streptokinase
    33  .


------------------------------------------------------------------------------------------------------------------------

Plain sentence:
---------------
    The biotechnology concern said the agreement between its longtime West German distributor, Boehringer-Ingleheim's Dr.
    Karl Thomae G.m.b.H. subsidiary, and Hoechst's Behringwerke subsidiary was an attempt to expand the market for
    blood-clot drugs in general.

Treebanked sentence:
--------------------
    The biotechnology concern said 0 the agreement between its longtime West German distributor , Boehringer - Ingleheim 's
    Dr. Karl Thomae G.m.b.H. subsidiary , and Hoechst 's Behringwerke subsidiary was an attempt *PRO* to expand the market
    for blood - clot drugs in general .

Tree:
-----
    (TOP (S (NP-SBJ (DT The)
                    (NN biotechnology)
                    (NN concern))
            (VP (VBD said)
                (SBAR (-NONE- 0)
                      (S (NP-SBJ (NP (DT the)
                                     (NN agreement))
                                 (PP (IN between)
                                     (NP (NP (NP (PRP$ its)
                                                 (NN longtime)
                                                 (ADJP (JJ West)
                                                       (JJ German))
                                                 (NN distributor))
                                             (, ,)
                                             (NP (NP (NNP Boehringer)
                                                     (HYPH -)
                                                     (NNP Ingleheim)
                                                     (POS 's))
                                                 (NML (NNP Dr.)
                                                      (NNP Karl)
                                                      (NNP Thomae)
                                                      (NNP G.m.b.H.))
                                                 (NN subsidiary))
                                             (, ,))
                                         (CC and)
                                         (NP (NP (NNP Hoechst)
                                                 (POS 's))
                                             (NNP Behringwerke)
                                             (NN subsidiary)))))
                         (VP (VBD was)
                             (NP-PRD (DT an)
                                     (NN attempt)
                                     (S (NP-SBJ (-NONE- *PRO*))
                                        (VP (TO to)
                                            (VP (VB expand)
                                                (NP (NP (DT the)
                                                        (NN market))
                                                    (PP (IN for)
                                                        (NP (NP (NML (NN blood)
                                                                     (HYPH -)
                                                                     (NN clot))
                                                                (NNS drugs))
                                                            (PP (IN in)
                                                                (NP (NN general))))))))))))))
            (. .)))

Leaves:
-------
    0   The
    1   biotechnology
    2   concern
    3   said
           prop:  say.01
            v          * -> 3:0,  said
            ARG0       * -> 0:1,  The biotechnology concern
            ARG1       * -> 4:1,  0 the agreement between its longtime West German distributor , Boehringer - Ingleheim
                                  's Dr. Karl Thomae G.m.b.H. subsidiary , and Hoechst 's Behringwerke subsidiary was an
                                  attempt *PRO* to expand the market for blood - clot drugs in general
    4   0
    5   the
    6   agreement
    7   between
    8   its
    9   longtime
    10  West
           name:  NORP               10-11  West German
    11  German
    12  distributor
    13  ,
    14  Boehringer
           name:  ORG                14-17  Boehringer - Ingleheim 's
    15  -
    16  Ingleheim
    17  's
    18  Dr.
           name:  ORG                18-21  Dr. Karl Thomae G.m.b.H.
    19  Karl
    20  Thomae
    21  G.m.b.H.
    22  subsidiary
    23  ,
    24  and
    25  Hoechst
           name:  ORG                25-25  Hoechst
    26  's
    27  Behringwerke
           name:  ORG                27-27  Behringwerke
    28  subsidiary
    29  was
           prop:  be.01
            v          * -> 29:0, was
            ARG1       * -> 5:2,  the agreement between its longtime West German distributor , Boehringer - Ingleheim 's
                                  Dr. Karl Thomae G.m.b.H. subsidiary , and Hoechst 's Behringwerke subsidiary
            ARG2       * -> 30:1, an attempt *PRO* to expand the market for blood - clot drugs in general
    30  an
    31  attempt
    32  *PRO*
    33  to
    34  expand
           prop:  expand.01
            v          * -> 34:0, expand
            ARG0       * -> 32:0, *PRO*
            ARG1       * -> 35:2, the market for blood - clot drugs in general
    35  the
    36  market
    37  for
    38  blood
    39  -
    40  clot
    41  drugs
    42  in
    43  general
    44  .


------------------------------------------------------------------------------------------------------------------------

Plain sentence:
---------------
    A Genentech spokeswoman said the agreement calls for Hoechst to promote TPA for heart patients and streptokinase for
    other clot-reducing purposes.

Treebanked sentence:
--------------------
    A Genentech spokeswoman said 0 the agreement calls for Hoechst to promote TPA for heart patients and streptokinase for
    other clot - reducing purposes .

Tree:
-----
    (TOP (S (NP-SBJ (DT A)
                    (NNP Genentech)
                    (NN spokeswoman))
            (VP (VBD said)
                (SBAR (-NONE- 0)
                      (S (NP-SBJ (DT the)
                                 (NN agreement))
                         (VP (VBZ calls)
                             (SBAR (IN for)
                                   (S (NP-SBJ (NNP Hoechst))
                                      (VP (TO to)
                                          (VP (VP (VB promote)
                                                  (NP-1 (NNP TPA))
                                                  (PP-2 (IN for)
                                                        (NP (NN heart)
                                                            (NNS patients))))
                                              (CC and)
                                              (VP (NP=1 (NNP streptokinase))
                                                  (PP-PRP=2 (IN for)
                                                            (NP (JJ other)
                                                                (ADJP (NN clot)
                                                                      (HYPH -)
                                                                      (VBG reducing))
                                                                (NNS purposes))))))))))))
            (. .)))

Leaves:
-------
    0   A
    1   Genentech
           name:  ORG                1-1    Genentech
    2   spokeswoman
    3   said
           prop:  say.01
            v          * -> 3:0,  said
            ARG0       * -> 0:1,  A Genentech spokeswoman
            ARG1       * -> 4:1,  0 the agreement calls for Hoechst to promote TPA for heart patients and streptokinase
                                  for other clot - reducing purposes
    4   0
    5   the
    6   agreement
    7   calls
           prop:  call.03
            v          * -> 7:0,  calls
            ARG0       * -> 5:1,  the agreement
            ARG1       * -> 8:1,  for Hoechst to promote TPA for heart patients and streptokinase for other clot -
                                  reducing purposes
    8   for
    9   Hoechst
           name:  ORG                9-9    Hoechst
    10  to
    11  promote
           prop:  promote.02
            v          * -> 11:0, promote
            ARG0       * -> 9:1,  Hoechst
            ARG1       * -> 12:1, TPA
            ARG2       * -> 13:1, for heart patients
    12  TPA
    13  for
    14  heart
    15  patients
    16  and
    17  streptokinase
    18  for
    19  other
    20  clot
    21  -
    22  reducing
    23  purposes
    24  .

